Exelixis (EXEL) Down 14.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/02/21
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021Business Wire • 11/20/21
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung CancerBusiness Wire • 11/09/21
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and DecemberBusiness Wire • 11/03/21
Exelixis, Inc. (EXEL) CEO Michael Morrissey on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 11/02/21
Wall Street Analysts Predict a 52% Upside in Exelixis (EXEL): Here's What You Should KnowZacks Investment Research • 10/26/21
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021Business Wire • 10/19/21
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying EnzymesBusiness Wire • 10/14/21
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin's LymphomaBusiness Wire • 10/14/21